Abstract

Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency. The control of serum uric acid level (UA) is important for prevention of TLS. Febuxostat has demonstrated its superiority over allopurinol in decreasing UA level. We retrospectively evaluated the efficacy of febuxostat 10 mg in prevention of hyperuricemia associated with TLS (HU-TLS) in 12 patients with non-Hodgkin’s lymphoma (NHL). Mean UA levels were found to significantly decrease (p = 0.003). HU-TLS was prevented in all patients. Thus, febuxostat 10 mg is effective in prevention of HU-TLS. Future study is need to determine whether the incidence of HU-TLS change with dosage of febuxostat.


Author Details

Authors

• Takeo Yasu
• Shunsuke Kobayashi
• Mai Horii
• Yosuke Kurokawa

Departments

• Department of Pharmacy, The Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Address

Takeo Yasu, PhD

The Research Hospital
The Institute of Medical Science
The University of Tokyo
4-6-1, Shirokanedai, Minato-ku,
Tokyo 108-8639, Japan

Email: yasutakeo-tky@
umin.ac.jp

Citation